Optimapharm Greece Consulting Research Single Member
Optimapharm Greece Consulting Research Single Member is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)
Sponsor Syndax Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A multicenter, randomized, double-blind, parallel, three-arm, active- and placebo-controlled therapeutic equivalence study for the comparison of clindamycin + tretinoin/Verisfield gel (1+0.025)% with Acnatac®/Meda gel [clindamycin + tretinoin (1+0.025)%] in the treatment of acne vulgaris.
Sponsor Verisfield Single Member S.A.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-ASPEN)
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination with DaratUMumab followed by Maintenance with Daratumumab in the Frontline Setting of Primary Plasma CEll LEukemIA: A Trial of the Greek Myeloma Study Group. The “EUMELEIA” Study
Sponsor Hellenic Society Of Hematology
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin’s Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy
Sponsor Fundacion Geltamo
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Prospective, Randomized, Open-label Phase 2b Study, with Blinded Evaluation, Comparing the Combination of Amodiaquine and Potassium Canrenoate with Either Exenatide or Glibenclamide Versus Best Medical Therapy, in Patients with Acute Ischemic Stroke
Sponsor Genesis Pharma S.A.
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors - The ADELA study-
Sponsor Medica Scientia Innovation Research S.L.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Optimapharm Greece Consulting Research Single Member?
The 2026-10-09 snapshot links Optimapharm Greece Consulting Research Single Member to 7 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Data management, Electronic data capture, among 11 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Optimapharm Greece Consulting Research Single Member?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Optimapharm Greece Consulting Research Single Member conducted?
The linked trials record locations in 14 countries, including Greece, Spain, Austria, Italy, Czechia. These are trial locations, not confirmed office locations or countries where Optimapharm Greece Consulting Research Single Member delivered services.
What can this page tell me about Optimapharm Greece Consulting Research Single Member's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Optimapharm Greece Consulting Research Single Member. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Optimapharm Greece Consulting Research Single Member S.A.